The investigation of miR-221-3p and PAK1 gene expressions in breast cancer cell lines

Gene

Volumn 555, Issue 2, 2015, Pages 377-381

  Ergun, Sercan ^a   Tayeb, Tayeb Sadiq ^a   Arslan, Ahmet ^a   Temiz, Ebru ^a   Arman, Kaifee ^a   Safdar, Muhammad ^a   Dağli, Hasan ^a   Korkmaz, Murat ^a   Nacarkahya, Gülper ^a   Kirkbeş, Sevil ^a   Oztuzcu, Serdar ^a  

^a GAZIANTEP UNIVERSITY   (Turkey)

Author keywords

Breast cancer; MiR 221 3p; PAK1; QRT PCR

Indexed keywords

ESTROGEN RECEPTOR ALPHA; MICRORNA; MICRORNA 221 3P; P21 ACTIVATED KINASE 1; SERINE; TAMOXIFEN; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; MIRN221 MICRORNA, HUMAN; P21 ACTIVATED KINASE; PAK1 PROTEIN, HUMAN;

3' UNTRANSLATED REGION; ARTICLE; BREAST CANCER CELL LINE; CONTROLLED STUDY; DISEASE SEVERITY; DOWN REGULATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MCF 7 CELL LINE; MOLECULAR MECHANICS; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; BREAST TUMOR; DRUG RESISTANCE; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHOSPHORYLATION; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; MICRORNAS; P21-ACTIVATED KINASES; PHOSPHORYLATION; REAL-TIME POLYMERASE CHAIN REACTION; TAMOXIFEN;

EID: 84920456732     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2014.11.036     Document Type: Article

References (25)

1. Ahmad S., Gupta S., Kumar R., Varshney G.C., Raghava G.P. Herceptin resistance database for understanding mechanism of resistance in breast cancer patients. Sci. Rep. 2014, 4:4483.
2. Arias-Romero L.E., Chernoff J. p21-activated kinases in Erbb2-positive breast cancer: a new therapeutic target?. Small GTPases 2010, 1(2):124-128.
3. Bay A., Coskun E., Oztuzcu S., Ergun S., Yilmaz F., Aktekin E. Evaluation of the plasma microRNA expression levels in secondary hemophagocytic lymphohistiocytosis. Mediterr. J. Hematol. Infect. Dis. 2013, 5(1):e2013066.
4. Davidson B., Konstantinovsky S., Kleinberg L., Nguyen M.T.P., Bassarova A., Kvalheim G., Nesland J.M., Reich R. The mitogen-activated protein kinases (MAPK) p38 and JNK are markers of tumor progression in breast carcinoma. Gynecol. Oncol. 2006, 102:453-461.
5. Dorssers L.C., Van der Flier S., Brinkman A., van Agthoven T., Veldscholte J., Berns E.M., Klijn J.G., Beex L.V., Foekens J.A. Tamoxifen resistance in breast cancer: elucidating mechanisms. Drugs 2001, 61(12):1721-1733.
6. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365(9472):1687-1717. Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
7. Giancotti V. Breast cancer markers. Cancer Lett. 2006, 243:145-159.
8. Grunewald T.G.P., Kammerer U., Schulze E., Schindler D., Honig A., Zimmer M., Butt E. Silencing of LASP-1 influences zyxin localization, inhibits proliferation and reduces migration in breast cancer cells. Exp. Cell Res. 2006, 312:974-982.
9. Hu X., Guo J., Zheng L., Li C., Zheng T.M., Tanyi J.L., Liang S., Benedetto C., Mitidieri M., Katsaros D., Zhao X., Zhang Y., Huang Q., Zhang L. The heterochronic microRNA let-7 inhibits cell motility by regulating the genes in the actin cytoskeleton pathway in breast cancer. Mol. Cancer Res. 2013, 11(3):240-250.
10. Jordan V.C. Tamoxifen (ICI46, 474) as a targeted therapy to treat and prevent breast cancer. Br. J. Pharmacol. 2006, 147(Suppl 1):S269-S276.
11. Ong C.C., Jubb A.M., Haverty P.M., Zhou W., Tran V., Truong T., Turley H., O'Brien T., Vucic D., Harris A.L., Belvin M., Friedman L.S., Blackwood E.M., Koeppen H., Hoeflich K.P. Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(17):7177-7182.
12. Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
13. Sağlik Bakanliği T.C. Sağlik I˙statistiği Yilliği 2012 http://sbu.saglik.gov.tr/Ekutuphane/kitaplar/istaturk2012.pdf.
14. Shiau A.K., Barstad D., Loria P.M., Cheng L., Kushner P.J., Agard D.A., Greene G.L. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998, 7:927-937.
15. Sivaraman V.S., Wang H., Nuovo G.J., Malbon C.C. Hyperexpression of mitogen-activated protein kinase in human breast cancer. J. Clin. Investig. 1997, 99:1478-1483.
16. Sorlie T., Perou C.M., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. PNAS 2001, 98:10869-10874.
17. Sorlie T., Tibshirani R., Parker J., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. PNAS 2003, 100:8418-8423.
18. Sun T., Yang M., Kantoff P., Lee G.S. Role of microRNA-221/-222 in cancer development and progression. Cell Cycle 2009, 8(15):2315-2316.
19. Urbich C., Kuehbacher A., Dimmeler S. Role of microRNAs in vascular diseases, inflammation, and angiogenesis. Cardiovasc. Res. 2008, 79(4):581-588.
20. Vanpoznak C., Seidman A.D. Encyclopedia of Cancer 2002, AcademicPress, Amsterdam, (287-299 pp.). 2nd edition.
21. Wang Y., Liu S., Zhang G., Zhou C., Zhu H., Zhou X., Quan L., Bai J., Xu N. Knockdown of c-Myce expression by RNAi inhibits MCF-7 breast tumor cells growth in vitro and in vivo. Breast Cancer Res. 2005, 7:R220-R228.
22. Yilmaz H.H., Yazihan N., Tunca D., Sevinç A., Olcayto E.Ö., Özgül N., Tuncer M. Cancer trends and incidence and mortality patterns in Turkey. Jpn. J. Clin. Oncol. 2011, 41(1):10-16.
23. Zhang X., Mao H., Chen J.Y., Wen S., Li D., Ye M., Lv Z. Increased expression of microRNA-221 inhibits PAK1 in endothelial progenitor cells and impairs its function via c-Raf/MEK/ERK pathway. Biochem. Biophys. Res. Commun. 2013, 431(3):404-408.
24. Zwart W., Griekspoor A., Berno V., Lakeman K., Jalink K., Mancini M., Neefjes J., Michalides R. PKA-induced resistance to tamoxifen is associated with an altered orientation of ERalpha towards co-activator SRC-1. EMBO J. 2007, 26(15):3534-3544.
25. Zwart W., Griekspoor A., Berno V., Lakeman K., Jalink K., Mancini M., Neefjes J., Michalides R. PKA-induced resistance to tamoxifen is associated with an altered orientation of ERa towards co-activator SRC-1. EMBO J. 2007, 26:3534-3544.